PIK3CA antibody (AA 936-1068)

Catalog No. ABIN3043462

This Rabbit Polyclonal antibody specifically detects PIK3CA in WB and FACS. It exhibits reactivity toward Humanand has been mentioned in 1 publication.

Quick Overview for PIK3CA antibody (AA 936-1068) (ABIN3043462)

Target: PIK3CA (Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PIK3CA antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS)

Product Details anti-PIK3CA Antibody

Binding Specificity: AA 936-1068

Purpose: Anti-PI 3 Kinase catalytic subunit alpha/PIK3CA Antibody Picoband®

Cross-Reactivity (Details): No cross-reactivity with other proteins

Characteristics: Anti-PI 3 Kinase catalytic subunit alpha/PIK3CA Antibody Picoband® (ABIN3043462). Tested in Flow Cytometry, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Purification: Immunogen affinity purified.

Immunogen: E.coli-derived human PIK3CA recombinant protein (Position: H936-N1068). Human PIK3CA shares 98% amino acid (aa) sequence identity with mouse PIK3CA.

Isotype: IgG

Application Details

Application Notes: Western blot, 0.1-0.5 μg/mL, Human
Flow Cytometry (Fixed), 1-3 μg/1x10⁶ cells, Human1.Hiles I, Otsu M, Volinia S, Fry M, Gout I, Dhand R et al. (August 1992). "Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit". Cell 70 (3): 419-29. 2.Ma Y, Wei S, Lin Y, Lung J, Chang T, Whang-Peng J et al. (May 2000). "PIK3CA as an oncogene in cervical cancer". Oncogene 19 (23): 2739-44. 3.Weigelt, B., Warne, P. H., Downward, J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30: 3222-3233, 2011.

Comment:

Antibody can be supported by chemiluminescence kit ABIN921124 in WB.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Concentration: 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl and 0.2 mg Na2HPO4.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C,-20 °C

Storage Comment: Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.

References for anti-PIK3CA antibody (ABIN3043462)

Wang, Sun, Li, Dong, Li, Zhao: "Resveratrol attenuates intermittent hypoxia-induced insulin resistance in rats: involvement of Sirtuin 1 and the phosphatidylinositol-4,5-bisphosphate 3-kinase/AKT pathway." in: Molecular medicine reports, Vol. 11, Issue 1, pp. 151-8, (2014) (PubMed).

Target Details for PIK3CA

Target: PIK3CA (Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA))

Alternative Name: PIK3CA

Background:

Synonyms: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform,PI3-kinase subunit alpha,PI3K-alpha,PI3Kalpha,PtdIns-3-kinase subunit alpha,2.7.1.153,Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha,PtdIns-3-kinase subunit p110-alpha,p110alpha,Phosphoinositide-3-kinase catalytic alpha polypeptide,Serine/threonine protein kinase PIK3CA,2.7.11.1,PIK3CA,

Tissue Specificity: Expressed in a number of cell lines of T-cell, B-cell and fibroblast origin. Strong expression in brain tissue.

Background: Phosphatidylinositol-4,5-bisphosphate 3-kinase, also called PIK3CA, is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. PIK3CA gene is mapped to 3q26.32. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate phosphatidylinositols (PtdIns), PtdIns4P andPtdIns(4,5)P2. Recent evidence has shown that the PIK3CA gene is mutated in a range of human cancers. It has been found to be oncogenic and has been implicated in cervical cancers. PIK3CA mutations in breast cancer may be a predictive marker to guide the selection of patients who would benefit from mTOR inhibitor therapy. In addition to that, the presence of PIK3CA mutation may predict response to aspirin therapy for colorectal cancer, indicating power and promise of "Molecular Pathological Epidemiology (MPE)" approach as well as a complex interaction within the tumor microenvironment in this phenomenon.

Sequence Similarities: Belongs to the PI3/PI4-kinase family.

Molecular Weight: 124 kDa

Gene ID: 5290

UniProt: P42336

Pathways: PI3K-Akt Signaling, RTK Signaling, TCR Signaling, AMPK Signaling, Interferon-gamma Pathway, TLR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Inositol Metabolic Process, Hepatitis C, CXCR4-mediated Signaling Events, Signaling Events mediated by VEGFR1 and VEGFR2, Signaling of Hepatocyte Growth Factor Receptor, VEGFR1 Specific Signals, VEGF Signaling